We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.76B
1-Year Est. Return
223.33%
This Fund
S&P 500
This Quarter
Est. Return
+30.59%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2B
AUM Growth
+$56.4M
(+2.9%)
Cap. Flow
+$172M
Cap. Flow
% of AUM
8.6%
Top 10 Holdings %
Top 10 Hldgs %
60.79%
Holding
62
New
5
Increased
3
Reduced
2
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZFOX
ZeroFox Holdings, Inc. Common Stock
ZFOX
|
+$150M |
| 2 |
Gossamer Bio
GOSS
|
+$43M |
| 3 |
ALLK
Allakos
ALLK
|
+$16.7M |
| 4 |
NOTE
FiscalNote
NOTE
|
+$14.2M |
| 5 |
TUYA
Tuya Inc
TUYA
|
+$7.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$27.2M |
| 2 |
Palo Alto Networks
PANW
|
+$17M |
| 3 |
VistaGen Therapeutics
VTGN
|
+$14.3M |
| 4 |
MILE
Metromile, Inc. Common Stock
MILE
|
+$8.61M |
| 5 |
Global E Online
GLBE
|
+$7.92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.51% |
| 2 | Technology | 14.18% |
| 3 | Industrials | 9.57% |
| 4 | Consumer Staples | 8.54% |
| 5 | Communication Services | 1.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Wheels Up
UP
$198M
| $1.22M | 0.06% |
5,306
| – | – |
|
|
PHAS
52
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $1.17M | 0.06% |
6,643,702
| – | – |
|
|
ADXN
53
Addex Therapeutics
ADXN
| $830K | 0.04% |
282,435
+235,363
| +500% | +$5.27M |
|
|
OBSV
54
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $652K | 0.03% |
4,586,563
| – | – |
|
|
TCON
55
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $579K | 0.03% |
17,336
| – | – |
|
|
AKTX
56
Akari Therapeutics
AKTX
$12.3M
| $285K | 0.01% |
565
| – | – |
|
|
57
Palo Alto Networks
PANW
$297B
| $22K | ﹤0.01% |
282
-196,494
| -100% | -$17M |
|
58
Enliven Therapeutics
ELVN
$4.43B
| – | – |
-251,681
| Closed | -$1.23M |
|
|
59
Global E Online
GLBE
$7.11B
| – | – |
-436,282
| Closed | -$7.92M |
|
|
60
VistaGen Therapeutics
VTGN
$12.8M
| – | – |
-543,420
| Closed | -$14.3M |
|
|
LUMO
61
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| – | – |
-65,374
| Closed | -$503K |
|
|
MILE
62
DELISTED
Metromile, Inc. Common Stock
MILE
| – | – |
-9,384,285
| Closed | -$8.61M |
|
Similar funds
NM
SLF
CGH
CIP
DF
HHAM
SFI
VCM
NEA Management Company's Q3 2022 Portfolio in Review
As of Q3 2022, NEA Management Company held 62 positions worth $2B, up 2.9% from $1.95B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
NEA Management Company deployed $172M of net new capital in Q3 2022, opening 5 new positions and adding to 3 existing holdings. Its largest new stake was ZeroFox Holdings, Inc. Common Stock: 18,090,861 shares worth $88.3M.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 69% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was CTI BioPharma Corp. (DE) Common Stock, an estimated $27.2M trimmed.
- NEA Management Company's largest Q3 2022 buy was ZeroFox Holdings, Inc. Common Stock: 18,090,861 shares worth $88.3M.
- NEA Management Company added most to Allakos in Q3 2022, an estimated $16.7M increase.
- NEA Management Company's biggest Q3 2022 reduction was CTI BioPharma Corp. (DE) Common Stock, cutting an estimated $27.2M.
- NEA Management Company fully exited VistaGen Therapeutics in Q3 2022, selling an estimated $14.3M.
- NEA Management Company's ten largest holdings make up 61% of its $2B portfolio in Q3 2022.
- NEA Management Company opened 5 new positions and closed 5 in Q3 2022.
- NEA Management Company's portfolio value rose 2.9% quarter-over-quarter to $2B.
Based on NEA Management Company's 13F filing for Q3 2022, filed 14 Nov 2022.